Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-05

Yanyan Qu

Role not yet determined Is this you? Add your title

Also affiliated: United States Food and Drug Administration (2026)

9 h-index 24 pubs 230 cited

Biography and Research Information

OverviewAI-generated summary

Yanyan Qu's research focuses on integrating in vitro and in silico methods, specifically New Approach Methodologies (NAMs), to improve the prediction of drug-induced liver injury. This work aims to enhance the accuracy and efficiency of toxicological assessments. Qu has published one study in this area, with a 2026 publication date, indicating recent activity in the field. Qu collaborates with Ting Li at the National Center for Toxicological Research, with one shared publication, suggesting a collaborative research environment.

Metrics

  • h-index: 9
  • Publications: 24
  • Citations: 230

Selected Publications

  • Integrating in vitro and in silico NAMs for enhanced prediction of drug-induced liver injury (2026)
    Drug Discovery Today DOI OpenAlex
  • Beyond QSARs: Quantitative Knowledge–Activity Relationships (QKARs) for enhanced drug toxicity prediction (2025)
    Toxicological Sciences 5 citations DOI OpenAlex
  • DILIrank 2.0: An updated and expanded database for drug-induced liver injury risk based on FDA labeling and a literature review (2025)
    Drug Discovery Today 5 citations DOI OpenAlex
  • DICTrank Is a Reliable Dataset for Cardiotoxicity Prediction Using Machine Learning Methods (2025)
    Chemical Research in Toxicology 6 citations DOI OpenAlex
  • Leveraging FDA Labeling Documents and Large Language Model to Enhance Annotation, Profiling, and Classification of Drug Adverse Events with AskFDALabel (2025)
    Drug Safety 17 citations DOI OpenAlex
  • A framework enabling LLMs into regulatory environment for transparency and trustworthiness and its application to drug labeling document (2024)
    Regulatory Toxicology and Pharmacology 14 citations DOI OpenAlex
  • Generation of a drug-induced renal injury list to facilitate the development of new approach methodologies for nephrotoxicity (2024)
    Drug Discovery Today 21 citations DOI OpenAlex
  • DICTrank: The largest reference list of 1318 human drugs ranked by risk of drug-induced cardiotoxicity using FDA labeling (2023)
    Drug Discovery Today 40 citations DOI OpenAlex
  • DICTrank: The largest reference list of 1318 human drugs ranked by risk of drug-induced cardiotoxicity using FDA labeling (2023)
    bioRxiv (Cold Spring Harbor Laboratory) 2 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

18 Collaborators 8 Institutions 3 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics